Quanterix Publishes Landmark Nature Study Redefining Alzheimer's Disease Prevalence

Simoa p-Tau 217 Assay Enables Largest Population-Based Assessment (11,000+ Samples) Revealing Striking Age-Related Increase and Broad Treatment Eligibility

Quanterix Corporation(NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced publication of a landmark study in the prestigious journal Nature. The study, which utilized Quanterix's ultra-sensitive Simoa p-Tau 217 (phosphorylated tau at threonine 217) research assay, is the largest population-based assessment of Alzheimer's Disease Neuropathological Changes (ADNC) to date, providing crucial, scalable data to redefine disease prevalence.